Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/110769
Title: | Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway |
Author: | Chaccour, Carlos Rabinovich, Regina |
Keywords: | Malària Assaigs clínics Malaria Clinical trials |
Issue Date: | 24-Apr-2017 |
Publisher: | Biomed Central |
Abstract: | The development of ivermectin as a complementary vector control tool will require good quality evidence. This paper reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be useful. Potential scenarios and pharmacological strategies are compared in order to help guide trial design. The rationale for a particular timing of an ivermectin-based tool and some potentially useful outcome measures are suggested. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.1186/s12936-017-1802-3 |
It is part of: | Malaria Journal, 2017, vol. 16, num. 1, p. 166 |
URI: | http://hdl.handle.net/2445/110769 |
Related resource: | http://dx.doi.org/10.1186/s12936-017-1802-3 |
ISSN: | 1475-2875 |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
chaccour2017_2515.pdf | 1.05 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License